


Unleash the Power of Multiplex Histology in Melanoma Research

Characterization of immune cell populations in the primary and metastatic melanoma tumor microenvironment can provide important insights into the mechanisms of response and resistance to checkpoint inhibitor immunotherapy, potentially leading to improved outcomes for patients with melanoma.

Experience matters when it comes to immunohistochemistry (IHC) and immunofluorescence (IF) protocols. At Cerba Research, our science-driven histology experts excel in developing complete and efficient IHC and IF assays, from preclinical models to validated tests for clinical trials.

We offer comprehensive services, including development, optimization, transfer, and fit-for-purpose validation, ensuring your study against melanoma reaches its ultimate goal.

Immune checkpoint inhibitors panel, CD8-CD3-LAG3-PD1-CTLA4, exploring the melanoma skin tumor microenvironment





Cerba Research

Oncology highlights


360+
Oncology trials supported globally

32
Authorizations and expansions enabled

80%
Trials involving specialty testing

Gold-standard melanoma research services in IHC and IF:

- Ready-to-use and custom protocol development
- Enhanced software image analysis
- Standard operating procedures, quality controls, and platforms in our histology laboratories
- Provision of healthy and diseased biological samples for your research purposes
- Following practice guidelines (e.g., NCCN melanoma guidelines - principles of biopsy and pathology)
- Access to pathologists experienced in melanocytic neoplasms
- A comprehensive array of IHC and IF protocols (250+ biomarkers)



(A) PD-L1 in metastatic melanoma. (B) Macrophage polarization in metastatic melanoma, CD68 (yellow) and CD163 (teal)

Other related services:

- Patient identification and recruitment
- Next-generation sequencing (NGS) – broad-panel assays with FFPE and circulating tumor DNA that include clinically relevant melanoma gene alterations such as BRAF and KIT
- Flow cytometry
- Nanostring™ (nCounter® and GeoMx®)
- PBMC isolation
- Circulating biomarkers
- Safety profile



© Cerba Research 2026

2026-17-08_FL_UPMHMR_V1

Cerba Research